DIAN DIAGNOSTICS GROUP CO.,LTD. Financials Dian Diagnostics Group Co.,Ltd.
Equities
300244
CNE1000015N1
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.13 CNY | -0.77% |
|
-1.60% | -40.66% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 13,731 | 21,269 | 20,829 | 15,754 | 14,881 | 8,753 | - | - |
| Enterprise Value (EV) 1 | 13,731 | 21,269 | 22,701 | 17,255 | 15,810 | 11,382 | 11,708 | 8,753 |
| P/E ratio | 39.5 x | 26.6 x | 18 x | 10.9 x | 48.4 x | 8.61 x | 6.98 x | 8.34 x |
| Yield | 0.58% | 0.38% | 0.4% | 0.8% | 0.25% | 1.02% | 1.44% | - |
| Capitalization / Revenue | 1.62 x | 2 x | 1.59 x | 0.78 x | 1.11 x | 0.58 x | 0.5 x | 0.48 x |
| EV / Revenue | 1.62 x | 2 x | 1.74 x | 0.85 x | 1.18 x | 0.75 x | 0.67 x | 0.48 x |
| EV / EBITDA | 12.7 x | 12.6 x | 10.1 x | 4.93 x | 11.3 x | 5.3 x | 4.07 x | 3.06 x |
| EV / FCF | 160 x | 19.5 x | 30.1 x | 24.4 x | 12.7 x | 9.57 x | 8.11 x | - |
| FCF Yield | 0.63% | 5.12% | 3.32% | 4.09% | 7.85% | 10.4% | 12.3% | - |
| Price to Book | 3.45 x | 4.53 x | 3.57 x | 2.12 x | 1.97 x | 1.08 x | 0.9 x | 0.85 x |
| Nbr of stocks (in thousands) | 620,458 | 620,458 | 620,458 | 626,898 | 624,979 | 619,450 | - | - |
| Reference price 2 | 22.13 | 34.28 | 33.57 | 25.13 | 23.81 | 14.13 | 14.13 | 14.13 |
| Announcement Date | 2/28/20 | 4/9/21 | 4/15/22 | 4/12/23 | 4/19/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8,453 | 10,649 | 13,083 | 20,282 | 13,408 | 15,126 | 17,568 | 18,331 |
| EBITDA 1 | 1,079 | 1,686 | 2,255 | 3,502 | 1,396 | 2,149 | 2,875 | 2,856 |
| EBIT 1 | 774.6 | 1,320 | 1,838 | 2,823 | 842.2 | 1,729 | 2,150 | 2,204 |
| Operating Margin | 9.16% | 12.4% | 14.05% | 13.92% | 6.28% | 11.43% | 12.24% | 12.03% |
| Earnings before Tax (EBT) 1 | 771.2 | 1,317 | 1,791 | 2,544 | 798.3 | 1,443 | 2,089 | 2,265 |
| Net income 1 | 347.3 | 802.9 | 1,163 | 1,434 | 307.5 | 1,026 | 1,266 | 1,061 |
| Net margin | 4.11% | 7.54% | 8.89% | 7.07% | 2.29% | 6.78% | 7.21% | 5.79% |
| EPS 2 | 0.5600 | 1.290 | 1.863 | 2.298 | 0.4918 | 1.641 | 2.023 | 1.694 |
| Free Cash Flow 1 | 85.95 | 1,090 | 753 | 706.4 | 1,242 | 1,189 | 1,444 | - |
| FCF margin | 1.02% | 10.23% | 5.76% | 3.48% | 9.26% | 7.86% | 8.22% | - |
| FCF Conversion (EBITDA) | 7.97% | 64.64% | 33.4% | 20.17% | 88.93% | 55.33% | 50.22% | - |
| FCF Conversion (Net income) | 24.75% | 135.72% | 64.75% | 49.25% | 403.83% | 115.9% | 114.02% | - |
| Dividend per Share 2 | 0.1280 | 0.1300 | 0.1350 | 0.2000 | 0.0600 | 0.1436 | 0.2037 | - |
| Announcement Date | 2/28/20 | 4/9/21 | 4/15/22 | 4/12/23 | 4/19/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,744 | 4,649 | 6,104 | 4,876 | 4,653 | 3,232 | 3,610 | 3,450 | 3,116 | 2,973 | 4,264 | 4,134 | 4,114 | 18,052 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | 60.03 | 1,082 | 1,501 | 814.1 | -575 | - | 419.2 | 252.7 | -190.2 | 102.9 | - | - | - | - |
| Operating Margin | 1.6% | 23.28% | 24.6% | 16.69% | -12.36% | - | 11.61% | 7.32% | -6.1% | 3.46% | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | 23.17 | - | - | - | 1,192 |
| Net margin | - | - | - | - | - | - | - | - | - | 0.78% | - | - | - | 6.6% |
| EPS 2 | -0.0900 | 1.209 | 1.810 | 0.8800 | -1.600 | 0.2554 | 0.4600 | 0.1300 | -0.3600 | 0.0371 | 0.5150 | 0.4550 | 0.4600 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/15/22 | 4/26/22 | 8/26/22 | 10/26/22 | 4/12/23 | 4/26/23 | 8/30/23 | 10/27/23 | 4/19/24 | 4/26/24 | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 1,872 | 1,501 | 929 | 2,630 | 2,956 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | 0.8302 x | 0.4288 x | 0.6655 x | 1.224 x | 1.028 x | - |
| Free Cash Flow 1 | 85.9 | 1,090 | 753 | 706 | 1,242 | 1,189 | 1,444 | - |
| ROE (net income / shareholders' equity) | 9.04% | 18.6% | 22.1% | 21.7% | 4.1% | 8.79% | 12.1% | 10.8% |
| ROA (Net income/ Total Assets) | 3.24% | 6.94% | 8.31% | 7.83% | - | 3.77% | 5.74% | 4.3% |
| Assets 1 | 10,709 | 11,575 | 13,996 | 18,325 | - | 27,236 | 22,063 | 24,677 |
| Book Value Per Share 2 | 6.420 | 7.570 | 9.420 | 11.90 | 12.10 | 13.10 | 15.70 | 16.70 |
| Cash Flow per Share 2 | 0.7800 | 2.490 | 2.120 | 2.620 | 3.060 | 2.310 | 2.730 | 4.140 |
| Capex 1 | 397 | 457 | 565 | 933 | 680 | 529 | 599 | 564 |
| Capex / Sales | 4.7% | 4.3% | 4.32% | 4.6% | 5.07% | 3.5% | 3.41% | 3.08% |
| Announcement Date | 2/28/20 | 4/9/21 | 4/15/22 | 4/12/23 | 4/19/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
14.13
CNY
Average target price
27.81
CNY
Spread / Average Target
+96.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.66% | 1.21B | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| +7.56% | 1.11B | |
| -15.34% | 1.03B |
- Stock Market
- Equities
- 300244 Stock
- Financials Dian Diagnostics Group Co.,Ltd.
